MARD

HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding

Retrieved on: 
Thursday, August 10, 2023
Research, General Health, Mobile, Wireless, Consumer Electronics, IOT (Internet of Things), Apps, Applications, Technology, Medical Devices, Health Technology, Clinical Trials, Science, Health, Diabetes, US Foods, American Diabetes Association, Wrist, The Wall Street Journal, Type 1 diabetes, BGM, Weizmann Institute of Science, Clarke Error Grid, Trial of the century, MARD, Blood, Patient, Conditional sentence, Bluetooth, Himawari (satellites), FDA, ADA, RF, Food, Medical device, The New York Times

He unveiled the data which included results in hypoglycemic levels demonstrating GWave’s unmatched accuracy and scalability of the product for the wellness and diabetic space.

Key Points: 
  • He unveiled the data which included results in hypoglycemic levels demonstrating GWave’s unmatched accuracy and scalability of the product for the wellness and diabetic space.
  • Employing its novel RF wave technology, GWave non-invasively and accurately monitors blood glucose levels in real time.
  • An innovative feature of the GWave device is its automated alert system, designed to inform users of any significant glucose level fluctuations.
  • In an impressive outcome, Dr. Hirsch lowered his glucose levels from 180 to 46 while GWave accurately monitored his blood glucose levels.

Know Labs Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Retrieved on: 
Wednesday, July 26, 2023
Health, Technology, General Health, Research, Science, Hardware, CGM, LightGBM, Data collection, Dexcom, Know Labs, MARD, Blood, Data, Machine learning, Algorithm, FDA, NYSE, Medical device

Know Labs, Inc. (NYSE American: KNW) today announced results from a new study titled, “ Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor .” The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs’ proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW) today announced results from a new study titled, “ Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor .” The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs’ proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%.
  • As with all Know Labs’ previous research, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6® continuous glucose monitor (CGM) as a reference device.
  • With this method, Know Labs was able to predict blood glucose in the test set – the dataset that provides a blind evaluation of model performance – with a MARD of 11.3%.
  • For 2023, Know Labs remains focused on refinement and external validation of its technology and contributing to its growing body of peer-reviewed evidence, which can be found at www.knowlabs.co/research-and-validation .

Know Labs’ Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy

Retrieved on: 
Tuesday, May 30, 2023
Biotechnology, Health Technology, Health, CGM, Blood, Arm, Diabetes, LightGBM, Data collection, Dexcom, Know Labs, Research, MARD, Data, Manuscript, Machine learning, Algorithm, Radio, FDA, NYSE, Data science, Medical device, Cryptocurrency

Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “ Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology .” The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs’ Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference (MARD) of 12.9% – which is within the range of FDA-cleared blood glucose monitoring devices.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “ Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology .” The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs’ Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference (MARD) of 12.9% – which is within the range of FDA-cleared blood glucose monitoring devices.
  • Like all previous Know Labs clinical studies, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6® continuous glucose monitor (CGM) as a proxy for the measurement of blood glucose.
  • Unique from previous studies, Know Labs tested new data science techniques and trained a lightGBM model to predict blood glucose using 1,555 observations – or reference device values – from over 130 hours of data collection across five healthy participants.
  • Our whole team is thrilled by these findings and the improved accuracy of our Bio-RFID technology as we continue to refine our approach,” said Ron Erickson, CEO and Chairman at Know Labs.

Shenzhen SiBionics Co., Ltd. to apply for CE certification for SIBIONICS CGM

Retrieved on: 
Tuesday, May 23, 2023
CGM, Exercise, CE, AGP, Diabetes, Continuous glucose monitor, Friends, Vibration, Ambulatory glucose profile, Research, Certification, MARD, Blood, Hypoglycemia, Patient, Glucose meter, Physician, APP, Himawari (satellites), Health, Medical device

SHENZHEN, China, May 23, 2023 /PRNewswire/ --  Shenzhen SiBionics Co., Ltd. has announced it is applying for CE certification, hoping to make SIBIONICS CGM benefit more diabetes patients and medical institutions, bringing them a better blood glucose monitoring experience, as well as refined and personalized health solutions, and contribute China's strength in health and peace.

Key Points: 
  • In November 2021, an innovative technology medical company in China, Shenzhen SiBionics Co., Ltd.(hereinafter referred to as SiBionics), launched China's first all-in-one calibration-free CGM (Continuous Glucose Monitoring) product - SIBIONICS CGM, which successfully demonstrated its innovation achievements in the field of medical devices.
  • SIBIONICS CGM can continuously monitor blood glucose 24 hours for 14 days, providing users with continuous, comprehensive, and reliable all-day blood glucose information.
  • SIBIONICS CGM adopts 5mm sensing electrodes, and the implantation pain when wearing the product is negligible.
  • It has 12 patents for invention of core technology of CGM products, and is a unicorn enterprise in China's medical innovation field.

ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Tuesday, May 9, 2023
CGM, Insurance, Diabetes, SENS, TSE, Safety, Physician, Blood glucose monitoring, BGM, MARD, Patient, Practitioner, Contour, NYSE, Medical device

PARSIPPANY, N.J., May 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.

Key Points: 
  • PARSIPPANY, N.J., May 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.
  • Created by Ascensia, the Eversense PASS program has been helping eligible patients in the U.S. access Eversense E3 and its benefits since April 2022.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

 Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring

Retrieved on: 
Friday, May 5, 2023
Hardware, FDA, Other Health, Technology, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Technology, Science, Biotechnology, Other Science, Health, Mobile, Wireless, Research, BGC, NN, Diabetes, Technical report, Informal technical report, AACE, Data collection, Dexcom, Know Labs, Pain, MARD, Data, Clutch (eggs), Radio, NYSE, Food, Software, Medical device, Medical imaging

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®.” Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®.” Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA.
  • From December 2022 through February 2023, Know Labs conducted a series of internal studies to validate the technical feasibility of its Bio-RFID™ sensor technology at quantifying blood glucose concentration (BGC) in five healthy participants, using the Dexcom G6® as a reference device.
  • Participants' BGC was monitored for three hours while readings from the Bio-RFID sensor and the Dexcom G6® were simultaneously logged.
  • Know Labs then used these data from the Bio-RFID sensor to train a NN model to predict BGC readings of the Dexcom G6® reference device.

Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin

Retrieved on: 
Monday, April 17, 2023
Medical Supplies, Medical Devices, Health, Diabetes, Health Technology, Managed Care, CGM, Insulin, Type 2 diabetes, CMS, Internal medicine, Multimedia, History, Medicare, Type 2, MARD, Hypoglycemia, MD, Patient, DXCM, Pharmaceutical industry, Dexcom

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events.

Key Points: 
  • Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events.
  • * The updated Medicare policy is the biggest single expansion of CGM coverage in the U.S. to date.
  • “The evidence is clear: Real-time CGM use helps people with diabetes on all types of insulin, not just mealtime insulin, achieve better glycemic outcomes.
  • Patients that don’t meet Medicare coverage criteria can take advantage of Dexcom’s pharmacy discount cash-pay program.

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch

Retrieved on: 
Monday, February 13, 2023
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Health Insurance, Biotechnology, Centers for Medicare & Medicaid Services, CGM, DXCM, Medicare, G7, Patient, Hypoglycemia, Ecosystem, Apple Watch, MARD, G6, Garmin, Pharmaceutical industry, Coal, Dexcom

Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.

Key Points: 
  • Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.
  • “When we set out to design G7, our goal was simple: to make the most accurate, easy-to-use CGM available for as many people with diabetes as possible,” said Kevin Sayer, chairman, president and CEO of Dexcom.
  • “The approval of Medicare coverage for G7 helps us deliver on that promise.
  • With Dexcom G7, the #1 recommended CGM brand8,9 now offers the most accurate1 and simple way to help people gain greater control of their diabetes.

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

Retrieved on: 
Tuesday, February 7, 2023
Biometrics, TV and Radio, Software, Music, Medical Devices, Football, Technology, Mobile, Wireless, Entertainment, Diabetes, Film & Motion Pictures, Sports, Marketing, Health, Advertising, Communications, Apps, Applications, Health Technology, Celebrity, Life, Hand, CGM, DXCM, Medicare, Type 2 diabetes, Patient, Hypoglycemia, Bowl game, Super Bowl, MARD, Disease, Pregnancy, Type 1, Type 2, Multimedia, Quality of life, Magic, Social media, Television, Pharmaceutical industry, Dexcom

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial , which announces the US launch of its next-generation Dexcom G7 CGM System.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial , which announces the US launch of its next-generation Dexcom G7 CGM System.
  • The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist, songwriter, actor and philanthropist, Nick Jonas.
  • View the full release here: https://www.businesswire.com/news/home/20230207005121/en/
    Nick Jonas on set during production of Dexcom's 2023 Super Bowl commercial launching its new Dexcom G7 CGM System.
  • (Photo: Business Wire)
    “Dexcom CGM has changed my life and revolutionized the way I take care of my health,” said Jonas.

Know Labs, Inc. Expands IP Leadership in Non-Invasive Diagnostics with New High Performance Glucose Sensor Patent

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Technology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Hospitals, Hardware, Algorithm, IP, Abbott Laboratories, Patent, United States patent law, United States Patent and Trademark Office, Internal, NYSE, Investment, FDA, CGMS-A, MARD, Laboratory, YSI, Medical imaging, Medical device, Dexcom

The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.

Key Points: 
  • The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.
  • 11,529,077, titled “High Performance Glucose Sensor,” was just issued by the United States Patent and Trademark Office.
  • This patent explicitly designates a MARD range of 5.0% to 9.9% for Know Lab’s non-invasive diagnostics technology platform.
  • “The high accuracy of the [Know Labs] non-invasive glucose sensor described herein, when compared to lower accuracy glucose sensors such as minimally invasive CGMs and fingerstick glucose sensors, means that the [Know Labs’] non-invasive glucose sensor can be used as a standard or reference sensor against which the accuracy of other glucose sensors are gauged.